menu
X

Given the current situation, we understand that people may experience worry and even fear about how their disease and treatment may impact their personal risk. Sanofi Genzyme is committed to patient safety and to transparent communication. We are taking COVID-19 seriously, and we are committed to updating the communities we serve with relevant information related to our medicines to help inform health decisions.

As COVID-19 has emerged only recently, there are no available data regarding the impact of the virus on our current therapies. At this time, if you have general questions about our therapies, you should consult the current U.S Prescribing Information (USPI).

Each patient’s situation is unique, and patients and their healthcare providers are in the best position to make decisions regarding their care. In addition to local public health authority guidance, and local guidance from medical or patient associations, more information about COVID-19 can be found on the Centers for Disease Control’s (CDC) website or the World Health Organization’s (WHO) website.

MAT-US-2001111

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

View IMPORTANT SAFETY INFORMATION

Lemtrada In The Body

MS is thought to occur when overactive immune cells attack healthy parts of the central nervous system. LEMTRADA is believed to work by targeting many of these cells that may cause relapsing forms of MS. It is not known exactly how LEMTRADA works in MS.

LEARN MORE ABOUT LEMTRADA IN THE BODY

In this video, Dr. Aaron Boster, a board-certified neuroimmunologist, talks about MS and LEMTRADA inside the body.

DURING TREATMENT

LEMTRADA RECOGNIZES
certain immune cells in the body, including those thought to cause relapsing MS.

LEMTRADA identifies certain immune cells

LEMTRADA REMOVES
many of those cells.

LEMTRADA removes many of those immune cells that are thought to cause relapsing MS

AFTER TREATMENT

YOUR IMMUNE SYSTEM
slowly begins to replace the cells that were removed with new cells.

For some people, certain cell types remain below normal levels when they were measured 1 year after treatment.

Immune system replaces the removed cells with new cells